AstraZeneca Pharma India Limited (NSE:ASTRAZEN)
7,827.50
-24.50 (-0.31%)
Apr 2, 2026, 3:29 PM IST
AstraZeneca Pharma India Revenue
AstraZeneca Pharma India had revenue of 6.12B INR in the quarter ending December 31, 2025, with 38.90% growth. This brings the company's revenue in the last twelve months to 21.77B, up 34.49% year-over-year. In the fiscal year ending March 31, 2025, AstraZeneca Pharma India had annual revenue of 17.16B with 32.48% growth.
Revenue (ttm)
21.77B
Revenue Growth
+34.49%
P/S Ratio
8.98
Revenue / Employee
36.29M
Employees
600
Market Cap
195.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | 8.14B | -182.50M | -2.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ipca Laboratories | 95.06B |
| Piramal Pharma | 88.71B |
| Emcure Pharmaceuticals | 88.50B |
| Alembic Pharmaceuticals | 72.67B |
| Gland Pharma | 61.13B |
| Ajanta Pharma | 52.02B |
| NATCO Pharma | 45.63B |
| Wockhardt | 31.74B |
AstraZeneca Pharma India News
- 3 days ago - AstraZeneca Pharma India appoints Dr. Shashank Srinivasan and promotes Mr. Venkat Natarajan - Business Upturn
- 14 days ago - AstraZeneca Pharma India announces resignation of non-executive director Jesús Diaz-Ropero Esteso - Business Upturn
- 17 days ago - AstraZeneca Pharma India receives approval to market Imfinzi for unresectable hepatocellular carcinoma - Business Upturn
- 7 weeks ago - ASTRAZEN shares fall over 4% as Q3 EBITDA drops 41.8% YoY to Rs 44.8 crore - Business Upturn
- 7 weeks ago - Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In First-Line Treatment - NDTV
- 3 months ago - AstraZeneca Pharma India receives CDSCO approval to import and market Datverzo in India - Business Upturn
- 4 months ago - AstraZeneca Pharma India jumps 3% after teaming up with Sun Pharma to boost access to Hyperkalaemia treatment in India - Business Upturn
- 4 months ago - AstraZeneca and Sun Pharma partner to boost access to Hyperkalaemia treatment in India - Business Upturn